Regulatory mechanisms of RANKL presentation to osteoclast precursors

Current Osteoporosis Reports

Volumn 12, Issue 1, 2014, Pages 115-120

  Honma, Masashi ^a   Ikebuchi, Yuki ^a   Kariya, Yoshiaki ^a   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Bone remodeling; Intracellular trafficking; OPG; Osteoblast; Osteoclast; Osteocyte; Osteoprotegerin; RANK; RANKL

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RAB27A PROTEIN; RAB27B PROTEIN; UNCLASSIFIED DRUG;

CELL SURFACE; CELL VIABILITY; CELLULAR DISTRIBUTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MEMBRANE FUSION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; UPREGULATION;

BONE REMODELING; CELL DIFFERENTIATION; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; OSTEOPROTEGERIN; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84895925063     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-014-0189-0     Document Type: Review

References (44)

1. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385-96. doi:10.1196/annals.1365.035. (Pubitemid 47092355)
2. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis. 2002;8(3):147-59. (Pubitemid 34535063)
3. Martin TJ, Ng KW. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J Cell Biochem. 1994;56(3):357-66. doi:10.1002/jcb.240560312. (Pubitemid 24360054)
4. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13(18):2412-24. (Pubitemid 29453612)
5. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-23.
6. Trambas CM, Griffiths GM. Delivering the kiss of death. Nat Immunol. 2003;4(5):399-403. (Pubitemid 36592428)
7. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059-66. doi:10.1359/JBMR.040305. (Pubitemid 41110556)
8. Silva I, Branco JC. Denosumab: recent update in postmenopausal osteoporosis. Acta Reumatologica Portuguesa. 2012;37(4):302-13.
9. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832-41. (Pubitemid 351229299)
10. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889-901. (Pubitemid 35460788)
11. Tanaka S, Nakamura I, Inoue J, Oda H, Nakamura K. Signal transduction pathways regulating osteoclast differentiation and function. J Bone Miner Metab. 2003;21(3):123-33. doi:10.1007/s007740300021. (Pubitemid 41184293)
12. Hikita A, Kadono Y, Chikuda H, Fukuda A, Wakeyama H, Yasuda H, et al. Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem. 2005;280(50):41700-6. (Pubitemid 41832232)
13. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem. 1998;273(43): 28355-9. (Pubitemid 28496137)
14. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 1999;4(6):353-62. (Pubitemid 29359450)
15. Tanaka S, Nakamura K, Takahasi N, Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 2005;208:30-49. doi:10.1111/j.0105-2896.2005. 00327.x. (Pubitemid 41746383)
16. Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation ismediated by the p38 signaling pathway. BiochemBiophys Res Commun. 2006;351(1):99-105. (Pubitemid 44635412)
17. Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, et al. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem. 2005;280(42):35209-16. doi:10.1074/jbc. M505815200. (Pubitemid 41532708)
18. Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 2004;279(25): 26475-80. doi:10.1074/jbc.M313973200. (Pubitemid 38798801)
19. Crotti TN, Flannery M, Walsh NC, Fleming JD, Goldring SR, McHugh KP. NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene. 2006;372:92-102. doi:10.1016/j.gene.2005.12.012.
20. Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, Tamura M, et al. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology. 1996;137(8):2187-90. (Pubitemid 26133995)
21. Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF. Establishment of an osteocyte-like cell line, MLO-Y4. J Bone Miner Res. 1997;12(12):2014-23. doi:10.1359/jbmr.1997.12.12.2014. (Pubitemid 27524478)
22. Zhao S, Zhang YK, Harris S, Ahuja SS, Bonewald LF. MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res. 2002;17(11):2068-79. doi:10.1359/jbmr.2002.17.11.2068. (Pubitemid 35239208)
23. •• Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231-4. doi:10.1038/nm.2452. This study showed that osteocytes are the major source of RANKL in physiological osteoclastogenesis.
24. •• Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235-41. doi:10.1038/nm.2448. This study showed that osteocytes are the major source of RANKL in physiological osteoclastogenesis.
25. Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res. 2009;24(4):597-605. doi:10.1359/jbmr.081210.
26. Herman BC, Cardoso L, Majeska RJ, Jepsen KJ, Schaffler MB. Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage. Bone. 2010;47(4):766-72. doi:10.1016/j.bone.2010.07.006.
27. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metabol. 2007;5(6):464-75. doi:10.1016/j.cmet.2007.05. 001. (Pubitemid 46825494)
28. • Kennedy OD, Herman BC, Laudier DM, Majeska RJ, Sun HB, Schaffler MB. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone. 2012;50(5):1115-22. doi: 10.1016/j.bone.2012.01.025. This study showed that RANKL/OPG ratio is up-regulated in osteocytes adjacent to the damaged site of bone.
29. Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997;82(9):3128-35. (Pubitemid 27385687)
30. Franz-Odendaal TA, Hall BK, Witten PE. Buried alive: how osteoblasts become osteocytes. Dev Dyn. 2006;235(1):176-90. doi:10.1002/dvdy.20603. (Pubitemid 46939715)
31. Kamioka H, Honjo T, Takano-Yamamoto T. A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone. 2001;28(2):145-9. (Pubitemid 32140970)
32. • Honma M, Ikebuchi Y, Kariya Y, Hayashi M, Hayashi N, Aoki S, et al. RANKL subcellular trafficking and regulatory mechanisms in osteocytes. J Bone Miner Res. 2013;28(9):1936-49. doi:10.1002/jbmr.1941. This study showed that osteocytes provide RANKL to osteoclast precursors through direct cell-cell interactions.
33. Honma M, Ikebuchi Y, Kariya Y, Suzuki H. Establishment of optimized in vitro assay methods for evaluating osteocyte functions. J Bone Miner Metab. 2014. doi:10.1007/s00774-013-0555-5.
34. Kariya Y, Honma M, Aoki S, Chiba A, Suzuki H. Vps33a mediates RANKL storage in secretory lysosomes in osteoblastic cells. J Bone Miner Res. 2009;24(10):1741-52. doi:10.1359/jbmr.090409.
35. Aoki S, Honma M, Kariya Y, Nakamichi Y, Ninomiya T, Takahashi N, et al. Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis. J Bone Miner Res. 2010;25(9):1907-21. doi:10.1002/jbmr.89.
36. Fukuda M. Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol Life Sci. 2008;65(18):2801-13.
37. Blott EJ, Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol. 2002;3(2):122-31.
38. Kariya Y, Honma M, Hanamura A, Aoki S, Ninomiya T, Nakamichi Y, et al. Rab27a and Rab27b are involved in stimulation-dependent RANKL release from secretory lysosomes in osteoblastic cells. J Bone Miner Res. 2010. doi:10.1002/jbmr.268.
39. Chavas L, Ihara K, Kawasaki M, Torii S, Uejima T, Kato R, et al. Elucidation of Rab27 recruitment by its effectors: structure of Rab27a bound to Exophilin4/Slp2-a. Structure. 2008;16(10): 1468-77.
40. Hume AN, Ushakov DS, Tarafder AK, Ferenczi MA, Seabra MC. Rab27a and MyoVa are the primary Mlph interactors regulating melanosome transport in melanocytes. J Cell Sci. 2007;120(Pt 17): 3111-22. (Pubitemid 47517093)
41. Stinchcombe J, Barral D, Mules E, Booth S, Hume A, Machesky L, et al. Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J Cell Biol. 2001;152(4):825-34.
42. Stinchcombe JC, Bossi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001;15(5):751-61. (Pubitemid 34008503)
43. Barral D, Ramalho J, Anders R, Hume A, Knapton H, Tolmachova T, et al. Functional redundancy of Rab27 proteins and the pathogenesis of Griscelli syndrome. J Clin Invest. 2002;110(2):247-57. (Pubitemid 34787362)
44. Fukuda M. Rab27 and its effectors in secretory granule exocytosis: a novel dockingmachinery composed of a Rab27.effector complex. Biochem Soc Trans. 2006;34(Pt 5):691-5. (Pubitemid 44796400)